Page 1

Press Release 2 March 2021 CRODA £ million £ million £ million Basic earnings per share ( EPS ) pence % Results for the year ended 31 December 2020 Strong strategic delivery built on resilient financial performance Croda International Plc ( " Croda " or the " Group " ) , the company that uses smart science to create high performance ingredients and technologies that improve lives , announces its full year results for the year ended 31 December 2020 . Highlights Adjusted¹ results Sales Core Business³ Operating profit Profit before tax ( PBT ) Return on sales4 Full year ended 31 December 2020 2019 % change reported rate % change constant rate² 1,293.9 1,265.9 2.2 % 2.3 % 319.6 339.7 ( 5.9 ) % ( 4.0 ) % 300.6 322.1 ( 6.7 ) % ( 4.8 ) % 175.5 185.0 ( 5.1 ) % n / a 23.0 24.7 ( 1.7 ) % pts n / a Free cash flow5 £ million 176.9 201.7 ( 12.3 ) % n / a Reported results ( IFRS ) 2020 2019 % change Sales Operating profit Profit before tax ( PBT ) Basic EPS Ordinary dividend per share Strong strategic delivery in 2020 £ million 1,390.3 1,377.7 0.9 % £ million 290.0 319.9 ( 9.3 ) % £ million 269.5 302.3 ( 10.9 ) % pence 155.1 172.8 ( 10.2 ) % pence 91.0 90.0 1.1 % • • Delivering for all stakeholders through our response to COVID - 19 ○ No employees furloughed or use of government liquidity ; supported customers , suppliers , employees and communities ○ Dividends paid in full ; 2020 full year dividend increased to 91.0p ( 52 % of adjusted EPS ) Living our Purpose : Smart science to improve lives ™ ○ Prioritising COVID - 19 vaccines and drug delivery activities Launched sustainability Commitment to be Climate , Land and People Positive by 2030 Increasing contribution from life science and consumer markets Accounting for over 80 % of Group profit О Enhancing growth , reducing cyclicality and expanding market opportunities ○ Fast - growing Health Care platform Accelerating strategic delivery with almost £ 1bn of organic and inorganic investments including Avanti and Iberchem acquisitions , part - funded by an equity placing raising gross proceeds of £ 627m Resilient financial performance • Limited adverse financial impact from COVID - 19 due to commitment of employees , strength of product portfolio , global footprint , customer intimacy and flexible manufacturing base • Group underlying sales 2.7 % lower ; Core Business constant currency ( CC ) sales growth of 2.3 % Steady month - on - month sales improvement in the second half in COVID - impacted sectors ; underlying Q4 sales • in line with prior year in Personal Care and returned to growth in Performance Technologies • Limited decline in adjusted operating profit of 5.9 % ( -4.0 % CC ) • Robust free cash generation ; leverage ratio of 1.8x EBITDA • IFRS profit before tax reduced to £ 269.5m ( 2019 : £ 302.3m ) , including impact of acquisitions 1